Thursday - May 22, 2025
Oral Investigational Agent Zoldonrasib Elicits Objective Responses in Patients With KRAS G12D-mutated Lung Cancer
April 27, 2025
PHILADELPHIA, Pennsylvania, April 27 [Category: Medical] -- The American Association for Cancer Research posted the following news release:

* * *

Oral Investigational Agent Zoldonrasib Elicits Objective Responses in Patients With KRAS G12D-mutated Lung Cancer

CHICAGO - Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced clinical benefit from the oral KRAS G12D inhibitor zoldonrasib, acco . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products